Evolent Health, Inc (NYSE:EVH) – Stock analysts at SunTrust Banks decreased their FY2019 earnings estimates for Evolent Health in a report released on Wednesday. SunTrust Banks analyst S. Draper now forecasts that the technology company will earn $0.41 per share for the year, down from their prior estimate of $0.46. SunTrust Banks has a “Buy” rating and a $30.00 price objective on the stock.

Evolent Health (NYSE:EVH) last announced its earnings results on Monday, August 7th. The technology company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. The firm had revenue of $107.30 million during the quarter, compared to the consensus estimate of $104.45 million. During the same quarter in the previous year, the company posted ($0.20) EPS. The firm’s revenue for the quarter was up 89.9% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/21/suntrust-banks-equities-analysts-cut-earnings-estimates-for-evolent-health-inc-evh.html.

EVH has been the subject of several other reports. BidaskClub downgraded Evolent Health from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Robert W. Baird reissued an “outperform” rating and issued a $35.00 price objective (up from $30.00) on shares of Evolent Health in a research note on Wednesday, June 14th. Leerink Swann reissued an “outperform” rating and issued a $32.00 price objective (up from $30.00) on shares of Evolent Health in a research note on Monday, June 19th. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Finally, Cowen and Company reissued an “outperform” rating and issued a $33.00 price objective (down from $35.00) on shares of Evolent Health in a research note on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Evolent Health currently has a consensus rating of “Buy” and a consensus price target of $29.33.

Shares of Evolent Health (NYSE EVH) traded up 2.038% on Thursday, reaching $16.275. 642,950 shares of the company traded hands. The company’s market capitalization is $1.07 billion. The firm has a 50-day moving average of $17.19 and a 200-day moving average of $17.19. Evolent Health has a 52-week low of $14.50 and a 52-week high of $25.66.

Hedge funds have recently modified their holdings of the business. ETF Managers Group LLC acquired a new position in Evolent Health in the 2nd quarter worth about $102,000. BNP Paribas Arbitrage SA increased its position in Evolent Health by 815.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock worth $120,000 after purchasing an additional 4,232 shares during the last quarter. US Bancorp DE increased its position in Evolent Health by 0.3% in the 1st quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock worth $126,000 after purchasing an additional 19 shares during the last quarter. Point72 Asia Hong Kong Ltd acquired a new position in Evolent Health in the 1st quarter worth about $126,000. Finally, Bank of Montreal Can increased its position in Evolent Health by 4,249.7% in the 1st quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock worth $138,000 after purchasing an additional 6,077 shares during the last quarter. 82.51% of the stock is currently owned by institutional investors.

In other Evolent Health news, CEO Steve Wigginton sold 6,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $25.07, for a total value of $150,420.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Frank J. Williams sold 16,300 shares of the company’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $23.73, for a total value of $386,799.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,366,132 shares of company stock worth $112,891,200. Insiders own 8.79% of the company’s stock.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.